Search Results for "Antagon"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Antagon. Results 11 to 15 of 15 total matches.

Drugs for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023  (Issue 1672)
— Anticholinergic drugs relax the detrusor muscle by antagonizing muscarinic receptors in the bladder. Six ...
In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age. Nonpharmacologic treatment, including bladder training, urge suppression, pelvic floor muscle exercises, constipation management, modification of fluid intake, and avoidance of dietary irritants such as alcohol and caffeine, should be tried first.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-5   doi:10.58347/tml.2023.1672a |  Show IntroductionHide Introduction

Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
of the toxic metabolite N-acetylp- benzoquinone imine (NAPQI). Salicylates can antagonize the uricosuric ...
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75   doi:10.58347/tml.2023.1688a |  Show IntroductionHide Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
antagonize dopamine to some extent and may reduce the efficacy of dopamine agonists. Concomitant use of any ...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 |  Show IntroductionHide Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
; 11:iii. 39. SD Comer et al. Depot naltrexone: long-lasting antagonism of the effects of heroin ...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44   doi:10.58347/tml.2023.1684a |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
-methyl-D-aspartate) receptor antagonist. NMDA receptor antagonism can be helpful when other opioids ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction